Rein Therapeutics, Inc. (RNTX) Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Rein Therapeutics Inc. NASDAQ:RNTX Healthcare · Biotechnology
Mkt Cap $57.8M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
Rein Therapeutics will present a late-breaking poster on inhaled LTI-03 in idiopathic pulmonary fibrosis at the European Respiratory Society 2026 Congress in Barcelona, running September 5-9, 2026.
The poster (PA6217, September 8 session on immunological mechanisms in pulmonary fibrosis) will be presented by Professor Philip Molyneaux of Imperial College London, and the underlying data has already been published in Nature Communications.
LTI-03 is a first-in-class inhaled peptide therapy derived from Caveolin-1 biology with U.S. Orphan Drug and Fast Track designations, and it is being tested in the randomized, placebo-controlled Phase 2 RENEW trial (NCT06968845).
RENEW is expected to enroll roughly 120 patients across the U.S., U.K., Australia, Poland, and Germany, with safety through Week 24 as the primary endpoint and change in forced vital capacity as the efficacy endpoint.
• 1mo ago AI analysis › Press Release
Rein Therapeutics to Present at Upcoming September Investor Conferences
Rein Therapeutics CEO Brian Windsor will present at the 2026 Cantor Global Healthcare Conference on September 11 and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, both in New York.
Live webcasts of both presentations will be available via the investor relations section of the Rein website, with archived replays accessible for approximately 90 days.
Rein is a clinical-stage biopharmaceutical company whose lead candidate LTI-03, a synthetic peptide with U.S. Orphan Drug and Fast Track designations, targets orphan pulmonary and fibrosis indications.
• 1mo ago AI analysis › Press Release
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics announced that the FDA has granted Fast Track designation to LTI-03 for the treatment of idiopathic pulmonary fibrosis (IPF).
This designation is intended to facilitate development and expedite the review of the drug, potentially enabling more frequent FDA interactions and eligibility for Accelerated Approval and Priority Review.
The company is actively enrolling approximately 120 patients in the Phase 2 RENEW trial across five countries and remains on track to report interim data in the second half of 2026.
• 2mo ago AI analysis › Press Release
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Rein Therapeutics reported that its Phase 2 RENEW trial of LTI-03 in IPF has surpassed 25% enrollment and remains on track to report interim data in the second half of 2026.
The company successfully completed an oversubscribed $57.5 million public offering, bringing its cash position to $43.6 million and extending its operational runway into the first quarter of 2028.
For the second quarter, the net loss narrowed to $6.4 million compared to $6.8 million in the prior year, driven by lower R&D and G&A expenses.
• 2mo ago AI analysis › Press Release
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
Rein Therapeutics published positive first-in-human clinical data for LTI-03 in Nature Communications, demonstrating safety and reduced markers of lung scarring in IPF patients. The randomized study showed significant reductions in key inflammatory markers at both 5 mg and 10 mg doses over 14 days.
At the higher 10 mg dose, LTI-03 reduced a direct marker of collagen deposition and showed SP-D reduction levels comparable to approved IPF therapies after twelve weeks of treatment. The study also suggested the drug may help preserve the lung's repair cells.
These results support the ongoing Phase 2 RENEW trial, which is expected to enroll 120 patients and will measure efficacy via change in forced vital capacity.
• 2mo ago AI analysis › Press Release
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
Rein Therapeutics announced that its Phase 2 RENEW trial of inhaled LTI-03 is now enrolling across all five planned countries, including Germany.
The randomized, placebo-controlled study targets approximately 120 patients with idiopathic pulmonary fibrosis (IPF) and utilizes change in forced vital capacity (FVC) as the primary efficacy endpoint.
Management confirmed that the trial remains on track to report initial topline data in the second half of 2026.
• 3mo ago AI analysis › Press Release
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
Rein Therapeutics announced that the first patient has been randomized in the United Kingdom for its Phase 2 RENEW trial of LTI-03 in idiopathic pulmonary fibrosis.
The company has enrolled 16 patients to date across sites in the US, Australia, and the UK, with two additional countries expected to join in coming months.
The trial aims to enroll approximately 120 patients total to evaluate safety, tolerability, and efficacy via forced vital capacity (FVC) changes.
• 4mo ago AI analysis › Press Release
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Rein Therapeutics closed a $57.5 million underwritten public offering of 57.5 million shares at $1.00 per share, including the full exercise of the over-allotment option.
The company intends to use the net proceeds to fully fund the Phase 2 RENEW trial of its lead asset LTI-03 in idiopathic pulmonary fibrosis and support operations into the first quarter of 2028.
The financing attracted new and existing healthcare-focused investors, including Adar1 Capital and Ikarian Capital, with Konik Capital Partners acting as underwriter.
• 5mo ago AI analysis › Press Release
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
Rein Therapeutics priced a $50 million underwritten public offering, issuing 50 million shares at $1.00 per share. Konik Capital Partners is acting as the sole book-running manager, with the offering expected to close on May 4.
The company plans to use the net proceeds to fully fund its ongoing Phase 2 clinical trial of LTI-03 in idiopathic pulmonary fibrosis. Based on its current operating plan, management believes the proceeds combined with existing cash will fund operations into 2028.
Underwriters were granted a 45-day option to purchase up to an additional 7.5 million shares to cover over-allotments. The offering consists entirely of common stock with no warrants attached.
• 6mo ago AI analysis › Press Release
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics has enrolled 8 patients to date in its Phase 2 RENEW trial evaluating LTI-03 for idiopathic pulmonary fibrosis, with two additional patients expected this week. Enrollment began in March 2026 and continues on a regular basis across an expanding global footprint.
Clinical sites are currently active in the United States, Australia, and Poland, with the United Kingdom and Germany expected to open in the near term to support ongoing recruitment.
The randomized, placebo-controlled study aims to enroll approximately 120 patients to evaluate the safety, tolerability, and efficacy of LTI-03, using change in forced vital capacity (FVC) as the major efficacy endpoint.
• 6mo ago AI analysis › 
